Detail akcie Edgewise Therap Rg online

Business Summary: Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on cardiovascular diseases. The Company is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardio metabolic conditions. The Company's pipeline comprises the EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003. EDG-7500 is a novel, oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction which is being studied in a multipart Phase 2 trial for the potential treatment of obstructive and nonobstructive HCM. The Company is also developing EDG-15400, which is in a Phase 1 trial of healthy adults with the future disease target of heart failure with preserved ejection fraction (HFpEF).
Financial Summary: BRIEF: For the six months ended 30 June 2026, Edgewise Therapeutics Inc revenues was not reported. Net loss increased 38% to $106.3M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.77302 to -$0.99018.